Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients

Biocon Ltd., India’s largest biotechnology company, released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for the treatment of diabetes.
The study included 264 patients poorly controlled on metformin, who were randomly chosen receive either IN-105 or placebo… Read more

Positive Results for Oral Insulin Delivery in Pre-Clinical Trials

MonoSol Rx and Midatech Group Ltd. anounced positive results from pre-clinical proof-of-concept studies for oral insulin delivery in Rhesus monkey studies and hope to begin human trials in 2011.
The two companies are developing insulin PharmFilm under a partnership that leverages MonoSol Rx’s… Read more

FDA Informs Mannkind It Needs More Time to Review AFREZZA NDA

The FDA informed MannKind Corporation that it would not be able to complete the review of the New Drug Application (NDA) for AFREZZA (insulin human [rDNA origin]) Inhalation Powder by the action date of December 29, 2010. The FDA stated that it will require approximately four additional weeks to complete its review of the NDA… Read more

Novo Nordisk to Develop Oral Insulin

Novo Nordisk has announced the signing of an exclusive Development and Licence Agreement with Emisphere Technologies, Inc. to develop and commercialize oral formulations ofNovo Nordisk’s insulins. This is the second license agreement between the two companies. The first agreement for the development of oral formulations of GLP-1 receptor agonists was signed… Read more

Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes… Read more

Novo Nordisk Starts Phase 1 Trial With Oral Insulin

Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). The aim of the trial, conducted in Germany, is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin in healthy volunteers and people with type 1 and type 2 diabetes… Read more

Novo Nordisk: Progress Made in Oral Insulin Development

Lars Sorensen, Novo’s chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years.
A number of companies have already tried to develop inhaled insulin, including Pfizer Inc, whose product Exubera, was discontinued in 2007. This form of insulin has raised concerns that it could cause lung damage. Read more

Subscribe to our Newsletter

Hide me